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This paper outlines an initial investigation of the bio-pharmaceutical industry (BPI) and the 
steps it is taking to meet the new FDA risk mandate.  It reviews the industry’s’ current strategy 
of improving its quality management systems that are central to achieving best practices within 
its operations. In addition the paper also reviews the strategy for upgrading to the next 
generation manufacturing execution systems which will control the enterprise facilities through 
full data integration and actionable intelligence. 
 
U.S. PHARMACEUTICAL INDUSTRY 
 
The U.S. life science industry is a business sector with high visibility which faces the significant task of developing, 
testing and manufacturing of pharmaceuticals. Within the complex environments in which bio-pharmaceuticals are 
developed, there is a strong need for IS systems that monitor, control and manage the production processes.   These 
industrial strength systems (Booch, 1994) can drive each of the steps within the product life cycle and are critical for 
guaranteeing that quality standards are met. The internal standards are set through quality assurance techniques 
developed from ‘best practices,’ while the external standards are set by the U.S. Food and Drug Administration 
(FDA).  
 
At the basis for FDA endorsement of industrial practices is the knowledge that system developers use standards that 
have been developed over time and have proven themselves through benchmarking and production experience (de 
Neufville, 2004).  Now the FDA has added to this traditional approach an additional criterion -- a risk analysis 
methodology (FDA, 2004).  Risk analysis has always been an informal part of monitoring and controlling the 
production life cycle, as well as a part of business process modeling, quality management, and continuous 
improvement. In fact business process modeling and best practices are strengthened by the formal acknowledgement 
of risk, and procedures for corrective and preventative actions (CAPA).   
 
This paper outlines an initial investigation of the bio-pharmaceutical industry (BPI) and the steps it is taking to meet 
the new FDA risk mandate. It is based on a review of pharmaceutical systems and discussions with technical staff at 
a large BP company about the role of information technology and system development. The outcome is a review of 
various IT systems and BPI plans for future development to meet this new risk criteria.  This research phase will 
serve as the basis for developing a more formal research proposal to study in-depth changes in the BP industry.   
 
U.S. FDA and RISK METHODOLOGY 
 
The FDA’s task is to apply rigorous oversight to the BPI to ensure the high standards, efficacy, and safety that the 
public demands. Throughout the research, development and manufacturing life cycle of drugs, vaccines, and other 
biological products, the FDA role is that of principal supervisory agency, assuring that industry best practices are 
followed (GAMP, 2001).  In addition, the FDA uses its oversight to guarantee that such issues as problems with 
contaminants and failed processes are identified and isolated. Following compliance guidelines, the FDA tracks and 
confirms that approved corrective and preventive actions (CAPA) are implemented. This results in an exceptionally 
low tolerance for variability or deviation in quality pharmaceutical products (FDA, 2003a; FDA, 2004). 
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In order to meet its mandate, the FDA has chosen a new risk-based paradigm for achieving its objectives as the 
principal oversight agency for the U.S. pharmaceutical industry. The rationale for this new risk model is the fact that 
its own internal guidelines state that the agency must follow a 2 year cycle in inspecting domestic BP facilities. Yet, 
its own internal review board has determined that the agency’s lack of staff, funds, and other resources prevent it 
from meeting its statutory responsibilities. The number of registered BP research and production sites keeps 
increasing, while the number of FDA visits and inspections have not kept up with the demand.  This backlog is well 
established and has forced the FDA to consider alternative approaches. Therefore in 2005 the Agency began piloting 
its risk methodology, outlined in part by the Pharmaceutical Current Good Manufacturing Practices (CGMPs) for 
the 21st Century (FDA, 2004).  
 
In essence, the risk resolving methodology is the metric for managing, controlling and prioritizing reporting and 
compliance tasks.  “The model is based on a risk-ranking and filtering method that is well-recognized, objective, and 
rigorously systematic. This approach should help the Agency make the best use of its limited surveillance and 
enforcement resources while maximizing the impact of those resources on the public health” (FDA, 2004).   
Risk management has become one the FDA’s principal tools in identifying, controlling, and reducing risks in 
pharmaceutical products and services.  Each of the steps in the FDA’s methodology is objective and verifiable, in 
that necessary critical data can be defined, captured and key performance indicators reported to the agency in a 
timely fashion (FDA, 2004). 
 
• Management pre-defines and identifies hazards, nonconformities, or sources of variability in the working 
environment. It then prioritizes the seriousness of the potential risk using FDA and industry standards. 
• The monitoring system triggers an operational alert when the pre-defined boundaries are exceeded. This 
serves as a marker for remediation.  
• In parallel, the integrated enterprise system triggers a system-wide alert and begins the risk log. This is 
necessary because the problem may affect a range of processes from raw materials to finished product.  
• The system then searches for the hazard, as well as the root cause(s) of the problem.  The corrective 
mechanisms within the system isolate the threat from the process and address the root cause(s). 
• The methodology is iterative, continually searching for and removing remaining residual risks until the 
operation conforms to the established industry standards.  
 
This methodology is straightforward, providing verifiable oversight throughout the phases of hazard definition, 
monitoring key performance indicators and system remediation (ICH, 2005).  The FDA then has the ability to use 
this feedback from the BPI to update its risk library concerning the frequency and severity of risk hazards for 
different production practices and design changes. Therefore both the BPI and the FDA have additional tools for 
capturing and controlling critical measurement of variability (FDA, 21CFR 820). 
 
In addition the FDA applies a comprehensive set of risk management statistics to the oversight and control data it 
evaluates. This information, combined with the BPI’s best business practices, permits an ongoing re-evaluation and 
reassessment of its working library of hazards (in terms of severity of each risk and the probability of occurrence).  
The FDA can build a corporate performance history and then schedule site visits and evaluations focusing on those 
key risk indicators (ICH, 2007). 
 
In the new FDA paradigm, BP companies are accountable for the success or failure of data integration and CAPA 
activities (FDA, 1999). For instance, if the supply chain system does not trigger an enterprise alert about a 
contamination failure, then this problem is both a production breakdown, as well as a failure in system integration 
and intelligence.  This situation when analyzed from a risk perspective shows that the system did not have the 
necessary level of data integration and CAPA procedures to meet the internal quality assurance standard and the 
external FDA risk review (Scott, 2002). 
  
This example shows the close relationship between risk and data integration in older legacy control systems. The 
pharmaceutical industry, like many older manufacturing environments, uses traditional production processes and has 
legacy information systems.  The work flow has been optimized for straightforward production and cost reductions, 
rather than for transparent information delivery and compliance. Furthermore, even though certain BP companies 
have begun to incorporate enterprise systems, their level of sophistication is such that it does not provide automated 
actionable intelligence or integrated CAPA functionality (Alavi, 2001).  
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Therefore a BP corporation has to address the following IT challenges to attain regulatory compliance: 
 
• Non-integrated production silos that trap critical information within their manufacturing processes.   
• Redundant and conflicting data that obfuscates analysis.  
• Incomplete CAPA communications and control.  
• Inability of process controls to trigger enterprise-wide problem remediation.  
• Legacy systems that inhibit compliance with the new mandate. 
 
Additional factors working against compliance include the need to invest significant capital, time and manpower to 




The BPI’s legacy sub-systems, developed for specific functional activities, lack complete connectivity with other 
enterprise systems. This should not be much of a surprise since these sub-systems were developed for specialized 
isolated tasks at a time when communication protocol standards were lacking and necessary hardware and software 
were deemed too expensive. 
 
But the situation is different today with the FDA, as well as BPI’s management, calling for integrated systems that 
work transparently. BP companies now face tactical and strategic choices on how to achieve this integration, since a 
wrong or even poor choice may over the long term negatively impact the corporate mission and FDA compliance. 
For instance, many large BP corporations have the following systems for their processes: 
 
Table 1:  BPI Vendor Systems. 
 
Functions  Vendor Systems 
  
Document Management GxPharma 
Laboratory and Production Maintenance Maximo 
Quality Assurance Management: 
Investigations & Laboratory Testing 
Trackwise 
Laboratory Information Reporting Multiple LIMS Systems  
Process Controls & Management Multiple Process Maintenance Systems 
Customer Complaints and Product 
 Quarantines & Recalls 
Trackwise 
Training ISOTrain 
Change Control/Management Trackwise 
Internal and Regulatory Reporting Trackwise 
 
 
Table 1 lists the functions commonly found in large BP corporations and some of the most popular vendors of those 
systems. The first thing that is evident in the table is that there are multiple vendor systems.  Yet in a general survey 
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Table 2: SAP R/3.  
SAP Enterprise Sub Systems 
 
Supply Chain Management System (SCMS)   
Supplier Relationship Management (SRM)  
Customer Relationship Management (CRM)  
Materials Management (MM)   
Quality Management (QM) 
Corrective and Preventive Actions  (QM-CAPA) 
 Laboratory Information Management System (LIMS) –  
 Advanced Planner and Optimizer (APO) 
 Plant Maintenance (PM) 
Environmental Health & Product Safety (EH&S)  
 
Table 2 shows an alternative system design whose modules are being evaluated or currently installed by many large 
BP companies. It is one based on enterprise integration using the SAP R/3 system.  These two tables represent the 
choices faced by large BP corporations: to either upgrade their current legacy systems or move to a new enterprise 
platform. In other words, the question is whether the best, most cost effective and straightforward path is to upgrade 
their legacy software to newer versions with communication services; or choose to move to a comprehensive 
enterprise system whose strong point is current and future data integration. 
 
Part of the answer and certainly one of the criteria in any evaluation is the ability of an enterprise system to achieve 
electronic enforcement of processes, where the manufacturing system executes established business rules to manage, 
control and enforce each step of the development and manufacturing process. These newer manufacturing execution 
systems (MES) like SAP QM and 2nd generation TW are replacing legacy software in providing the necessary 
integration fabric to meet quality production and the FDA mandate.  These are in fact the first generation of MES 
that begin to offer some automated electronic enforcement and intelligent CAPA responses (FDA, 21CFR 820), as 
well as more integrated supply chain management.  Their reporting and control systems can also form the basis for 
documenting and demonstrating FDA compliance (FDA, 2003b).   
 
Similarly, this type of system would ensure that corporate standard operating procedures (SOPs) and best practices 
are followed using FDA guidelines.  When a rule is not followed, or data readings are missing or exceeding 
specifications, the system triggers an alarm, alerting appropriate personnel and recording the event and 
automatically implementing CAPA responses to contain and resolve the problem.  In this manner the system 
documents the workflow, tracking key performance indicators, and building an audit trail for FDA reporting.  Part of 
this audit trail consists of tracking production and drilling down to data by product line, specific batches, serial 
number and ingredients, irrespective of data sub system or platform. The audit trail meets FDA guidelines by 
reporting the hazard, CAPA activity timeframe, and the outcome in reducing or eliminating the threat. 
 
MANUFACTURING EXECUTION SYSTEMS 
 
Many BP companies are currently using a combination of a legacy system with SAP R/3 components. (See Tables 1 
and 2.)  The critical question facing the BPI is whether they upgrade their current legacy systems or take the step of 
switching to a SAP enterprise system. This paper reviews the problem comparing two systems which have MES 
features: 2nd generation Trackwise (TW), which is a multi-functioning quality management (QM) system and its 
competitor QM (CAPA) from SAP R/3.  
It is important to understand that 1st generation TW version 6.0 is being used in many large BP corporations, which 
means that upgrading to 2nd generation TW is a much easier step than switching to SAP. The TW 2004 version 6.0 
has as its main module quality management (QM), with additional modules for governance risk and compliance, 
change control, environmental health / safety, action tracking / reporting, IT integration and other support 
applications. It has customers among the largest in the field of life sciences, and is considered one of the premier 
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products in the industry. In this investigation of a large BP corporation it was found that TW was used in four of the 
major functional areas mentioned. Most users interviewed were impressed with TW’s ability to highlight 
manufacturing deviations and trap problems. TW’s QM sub-system has the capability to capture a variance in a 
given standard or production process, call a system wide alert and place a system wide injunction on all related 
processes, while maintaining supervision until a successful outcome is reached.  Therefore TW has been used for a 
range of services from nonconformance and customer complaints to supplier quality issues, internal / FDA external 
audits and preventive maintenance. 
These are noteworthy features, though they do not meet the future criteria of automatic execution of MES activities.  
The standard that BP corporations are aiming for in their operations is full, complete and automatic electronic 
enforcement, where the QM system can execute a series of risk management activities, rather than just sounding an 
alert and recording the manual activities of staff.  The TW 2004 version 6.0 described above is a release that lacks 
full cross functional communications with the other systems shown in Table 1 or SAP functions in Table 2.  The 
reason for this has to do with telecommunication linkages, the legacy nature of some of the other functioning sub-
systems, and the different product naming conventions found in SAP R/3. 
Therefore BP companies, if they intend to keep TW as one of their principal systems, must upgrade to gain a higher 
level of electronic enforcement, integration, and a naming convention that is parallel to SAP R/3.  This last factor is 
important, since SAP is dominant in BP supply chain management, and therefore any future MES platform needs to 
interact with it to resolve issues such as contamination and quality of raw materials.  
 
Furthermore, TW faces the future problem of always trying to maintain compatibility with SAP’s modules, as well 
as with other vendors that are publishing new releases of software. Using the legacy TW version 6.0 software can 
illustrate this problem.  Let us assume that there is a production problem resulting from contaminated raw materials. 
TW would highlight the problem and alert staff and issue an injunction on activities.  Much of the investigation data 
would be manually collected and analyzed.  Table 3 illustrates TW 6.0’s level of data integration at a typical 
pharmaceutical company in the 2007 timeframe for working through the investigation and problem resolution. Since 
it is limited, much of the work in determining the source of the contamination would be done manually.  For 
instance, a typical question that staff must resolve about a contamination problem: is it from raw materials and 
therefore a part of supply chain issue, or is it caused by a machine miscalibration on the manufacturing floor, or 
finally a misplaced SOP update. 
 
Table 3: TW and SAP QM integration comparison. 
 
Data Integration Across Systems  TrackWise 6.0  SAP QM 
Bill-Of-Materials Integration  No Yes 
Supply Chain Management System  Partial Yes 
Human Resources personnel  No Yes 
Lot hierarchy and batch search and analysis No Yes 
Event tracking and trending Yes Yes 
Assigning and tracking Investigation Partial Yes 
Compliance with FDA’s 21 CFR Part 11   Yes Yes 
Compliance with Internal  conformance standards Yes Yes 
 
Table 3 also compares the ability of TW and the SAP Quality Management (QM) system to receive or transfer data 
between different functional areas.  The table shows that data is trapped within TW and can not fully cross systems, 
whether it is to SAP, or to other tasking software such as that found in Table 1.  It is not surprising that SAP QM 
comes off as more integrated since for the most part it was designed to integrate with its other SAP software 
modules. Furthermore since SAP has become one of the major ERP standards in the BP industry, many smaller 
vendors have adopted its naming conventions and communication protocols. 
 
The TW system is well regarded in the industry and was widely adopted when it first entered the market place, since 
it effectively tracked and managed problems, while documenting compliance issues.  So initially there was strong 
justification for its adoption, as it was the best fit for managing and controlling production at the time.  In addition, 
there were few competitors, since SAP QM with integrated CAPA was only introduced in the marketplace in 2005.  
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Therefore many BP companies made the correct decision in choosing TW as the best available in the time period 
between 1995 and 2005.  
Now there still remains a strong rationale for choosing the TW upgrade: 
 
• BP user community familiarity with the TW system, 
• Proven as a strong performer with quality management functions, 
• Expanded data integration and interconnectivity with other programs, particularly with SAP. 
 
TW upgrade claims still need to be verified in terms of the interoperability and functionality of its new version of 
QM software.  They also need to be verified with every new TW software release to determine that the data 
integration and interconnectivity functions still work. Furthermore TW software needs to be retested against any 
new SAP product release, as well as GxPharma and other products that are installed, for there is always a risk of a 
connectivity failure. In addition to the telecommunications link, there are questions about future data dictionary 
integration.  The TW upgrade must be checked against every new release of SAP, to be sure that the entity naming 
conventions found in the database and data dictionary have not changed.  This logic holds true with future releases 
of other vendors, for they too must be tested for data dictionary consistency to catch divergent names for products, 
materials, and equipment.  
 
It is up to the BP companies to fully test and evaluate the compatibility claims of TW and other vendors, though it is 
clearly realized that some claims can only be evaluated through actual use.  Alternatively some claims can be 
verified by the shared experience of the BPI, assuming that they have the same set of vendor software.  
 
Those that are against the TW upgrade prefer to focus on the SAP integrated platform for the pharmaceutical 
industry. Some Quality Assurance and IT staff that were interviewed argue that with the new FDA risk initiative, 
and with the continual growth and expansion of SAP R/3 in marketplace, their corporation should take the step in 
switching to this unified platform.  This argument has merit since SAP-QM / CAPA software integrates fully into 
the enterprise SAP/R3 modules and with MySAP work portal.  This allows for data to flow across boundaries for 
production purposes as well as for defining work roles, passing information and assigning tasks within MySAP. 
 
Since pharmaceutical companies are at a crossroads, it makes sense to do this type of evaluation before upgrading 
vendor software or replacing it with SAP R/3 modules which provide the same type of functionality, with potentially 
superior integration and communications.  Lastly, these firms must weigh the long term potential of SAP R/3 to 
develop into a fully functioning MES platform, with close integration, transparency and electronic enforcement.  
 
DECISION MAKING CRITERIA 
     
To reach resolution on the best way for BP corporations to proceed, there are several helpful IT methodologies that 
inform the decision making process.  These are spelled out by the Enterprise Risk Management (ERM) framework 
described by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) and those of IT 
Governance Institute’s (ITGI) COBIT 4.0 methodology. The idea of an MES platform fits within the ERM 
framework, as corporations are building a broad enterprise-wide system for internal controls and quality assurance. 
Similarly, the ITGI’s framework develops a roadmap for data integration and transparency. In fact the Enterprise 
Risk Management (ERM) framework includes the ITGI best practices.  Therefore it is fair to say that both the ERM 
and COBIT support the development of an infrastructure to manage risk and performance.   
These functional processes that ERM and COBIT describe are in fact comparable in nature and function to an MES 
which provides analytics and integration for production.  
Some of the characteristics of this type of system for the pharmaceutical industry are its ability to incorporate 
actionable activity from: 
  
• FDA regulations  
• Corporate policies and procedures  
• Corporate environment for risk management with supporting surveys  
• Industry best practice mandates with supporting evidence 
• Test plans with test outcomes 
• Business process flows, theoretical and actual  
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• Risk libraries with stored CAPA plans and self activated procedures 
• Control libraries documenting control history  
• Evidence for compliance in a transparent electronic format 
 
MES analytics and integration are described more fully in Table 4. The more sophisticated and encompassing the 
MES outlined in this table the greater the chance that this will be a knowledge management system that meets the 
compliance mandate of the FDA (Maier, 2004).  Its functionality permits on one hand the codifying and storing of 
best practices and critical data.  On the other hand, it provides active management of risk accounting and fault 
management (Scott, 2002).  It is direct and focused for FDA oversight, and provides the foundation for further steps 
as the FDA matures and adopts specifications similar to ERM and COBIT, and can be used to assess the choice 
between upgrading disparate systems or choosing an integrated system such as SAP (Adis, 2007). 
 
The next stage of research will be to see if the COBIT / ERM methodology can be specifically tailored for use in the 




Much of the initial findings from this exploration of the BP industry concern the new FDA risk mandate and how it 
drives the change to new systems. Parallel with these internal technological steps, the BPI is tracking new 
developments from software vendors, initiatives by the FDA, changes in hardware, SOA software and 
communications protocols. This is because the BPI realizes that only through new IT platforms can corporations 
achieve the necessary level of best practices and compliance.  
 
At the center of the planned development will be an MES platform, with functionality to provide integration, 
enforceable intelligence and FDA risk tracking.  The initial findings indicate that an enterprise IT platform from a 
leading vendor such as SAP will likely provide the most pragmatic, integrated approach to risk management, 
compliance, analytics, and control.  
 
Table 4:  MES Functionality. 
 
Repository  Management Risk Component 
Regulatory database  Data repository of regulatory standards and critical 
measurements 
Best Practices database Industry standard procedures 
Compensatory Services CAPA programs and procedures with triggers  
Process Management  
Mapping of processes Detailed description of processes and risks  
Logistic tracking  Tracking of resources, products, processes 
Data comparison Analysis of critical measurements and variability  
Change tracking Monitoring change in the process 
Design optimization Planning for performance upgrades  
Audit Audit trail showing data creation, modification, 
deletion 
Plug and play configuration Incorporating new systems 
Fault Management  
Alarm notification Alerting staff and control hardware of faults 
Alarm correction  Switching, and isolating supplies, processes and 
products  
Disaster recovery Isolating and recovering from disasters; logging 
activities, switching over to redundant systems  
Remote process Modifying process using CAPA   
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reconfiguration 
Performance Management  
Capacity planning Tracking production growth 
Event scheduling Balancing production loads of scheduled processes 
Process analysis Analyzing for errors and faults, using best 
practices 
Test monitoring Testing samples for quality and performance 
Trouble ticketing Resolving known problems and replacing defects 
Information Management  
Data backup Securing data and configuration information 
Monitoring and testing 
control mechanisms 
Checking system controls with test data  
Creating transparency for 
internal usage and for 
Regulatory Agency 
Shared protocols for transferring information 
internally and externally 
Developing dashboards to 
quantify risks  
Straightforward visual metering of risk and 
performance levels  
Firewall filtering services Screening the information repository and 
monitoring against foreign activity  
 
 
The consensus is that this is superior to multiple platforms using various linking protocols and matching 
data dictionaries. This latter option introduces a layer of complexity that IT staff would prefer to avoid 
(Tiwana, 2000). The criteria therefore in choosing SAP over its competitors come down to this: its 
platform has the greater likelihood of achieving data integration, transparency and electronic enforcement 
as well as provide verifiable FDA compliance.  The rationale is to use SAP as the principal platform, 
leveraging its integration and analytics, and link it temporarily to other vendor software until that point in 
time when SAP develops the same corresponding modules.  This step takes advantage of the SAP 
infrastructure, its portal MySAP for dashboard analytics, and its NetWeaver integration services with its 
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